Around a year ago, Ameet Mallik left his post at Novartis, where he had spent the last 16 years, to champion a drug for metastatic pancreatic cancer as CEO at Rafael Holdings. However, just half a year in, the company took a nosedive as that drug failed a Phase III trial, and Mallik, among many others, left Rafael Holdings.
Now Mallik will be starting fresh as CEO of ADC Therapeutics, the company announced today.
He will be taking the reins from Chris Martin, who helped co-found the biotech in 2011 and built it to more than 300 employees. Martin will remain on as a non-executive member of the board, and he’ll serve as an advisor over the next three months during the company’s transition phase after helping built it from
“I have had the privilege of taking our proprietary ADC technology from discovery to the…
Click here to view original post